Gast ::
| Hauptseite > Publikationsdatenbank > Convenient PET-tracer production via SuFEx 18F-fluorination of nanomolar precursor amounts > print |
| Hauptseite > Publikationsdatenbank > Convenient PET-tracer production via SuFEx 18F-fluorination of nanomolar precursor amounts > print |
| 001 | 907585 | ||
| 005 | 20230217124544.0 | ||
| 024 | 7 | _ | |a 10.1016/j.ejmech.2022.114383 |2 doi |
| 024 | 7 | _ | |a 0009-4374 |2 ISSN |
| 024 | 7 | _ | |a 0223-5234 |2 ISSN |
| 024 | 7 | _ | |a 1768-3254 |2 ISSN |
| 024 | 7 | _ | |a 2128/31129 |2 Handle |
| 024 | 7 | _ | |a altmetric:128215498 |2 altmetric |
| 024 | 7 | _ | |a pmid:35447431 |2 pmid |
| 024 | 7 | _ | |a WOS:000793618400001 |2 WOS |
| 037 | _ | _ | |a FZJ-2022-02092 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Walter, Nils |0 P:(DE-Juel1)180982 |b 0 |
| 245 | _ | _ | |a Convenient PET-tracer production via SuFEx 18F-fluorination of nanomolar precursor amounts |
| 260 | _ | _ | |a Amsterdam [u.a.] |c 2022 |b Elsevier |
| 264 | _ | 1 | |3 print |2 Crossref |b Elsevier BV |c 2022-07-01 |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1652072097_4713 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Recently, a protocol for radiolabeling of aryl fluorosulfates (“SuFEx click radiolabeling”) using ultrafast18F/19F isotopic exchange has been reported. Although promising, the original procedure turned out to berather inefficient. However, systematic optimization of the reaction parameters allowed for developmentof a robust method for SuFEx radiolabeling which obviates the need for azeotropic drying, base additionand HPLC purification. The developed protocol enabled efficient 18F-fluorination of low nanomolaramounts of aryl fluorosulfates in highly diluted solution (micromolar concentrations). It was successfullyused to prepare a series of 29 18F-fluorosulfurylated phenols e including modified ezetimibe, atocopheroland etoposide, the two tyrosine derivatives Boc-Tyr([18F]FS)-OMe and H-Tyr([18F]FS)-OMe,the FAP-specific ligand [18F]FS-UAMC1110, and the DPA-714 analog [18F]FS-DPA e in fair to excellentyields. Preliminary evaluation demonstrated sufficient in vivo stability of radiofluorinated electron rich orneutral {Boc-Tyr([18F]FS)-OMe), H-Tyr([18F]FS)-OMe and [18F]FS-DPA} aryl fluorosulfates. Furthermore,[18F]FS-DPA was identified as a promising tracer for visualization of TSPO expression |
| 536 | _ | _ | |a 5253 - Neuroimaging (POF4-525) |0 G:(DE-HGF)POF4-5253 |c POF4-525 |f POF IV |x 0 |
| 542 | _ | _ | |i 2022-07-01 |2 Crossref |u https://www.elsevier.com/tdm/userlicense/1.0/ |
| 542 | _ | _ | |i 2022-07-01 |2 Crossref |u https://doi.org/10.15223/policy-017 |
| 542 | _ | _ | |i 2022-07-01 |2 Crossref |u https://doi.org/10.15223/policy-037 |
| 542 | _ | _ | |i 2022-07-01 |2 Crossref |u https://doi.org/10.15223/policy-012 |
| 542 | _ | _ | |i 2022-07-01 |2 Crossref |u https://doi.org/10.15223/policy-029 |
| 542 | _ | _ | |i 2022-07-01 |2 Crossref |u https://doi.org/10.15223/policy-004 |
| 588 | _ | _ | |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de |
| 700 | 1 | _ | |a Bertram, Jan |0 P:(DE-Juel1)191040 |b 1 |
| 700 | 1 | _ | |a Drewes, Birte |0 P:(DE-Juel1)131817 |b 2 |
| 700 | 1 | _ | |a Bahutski, Victor |0 P:(DE-Juel1)172894 |b 3 |
| 700 | 1 | _ | |a Timmer, Marco |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a Schütz, Markus B. |0 0000-0003-3381-2729 |b 5 |
| 700 | 1 | _ | |a Krämer, Felicia |0 P:(DE-Juel1)186984 |b 6 |
| 700 | 1 | _ | |a Neumaier, Felix |0 P:(DE-Juel1)175142 |b 7 |e Corresponding author |
| 700 | 1 | _ | |a Endepols, Heike |0 P:(DE-Juel1)180330 |b 8 |
| 700 | 1 | _ | |a Neumaier, Bernd |0 P:(DE-Juel1)166419 |b 9 |e Corresponding author |
| 700 | 1 | _ | |a Zlatopolskiy, Boris D. |0 P:(DE-Juel1)176188 |b 10 |
| 773 | 1 | 8 | |a 10.1016/j.ejmech.2022.114383 |b Elsevier BV |d 2022-07-01 |p 114383 |3 journal-article |2 Crossref |t European Journal of Medicinal Chemistry |v 237 |y 2022 |x 0223-5234 |
| 773 | _ | _ | |a 10.1016/j.ejmech.2022.114383 |g Vol. 237, p. 114383 - |0 PERI:(DE-600)2005170-0 |p 114383 |t European journal of medicinal chemistry |v 237 |y 2022 |x 0223-5234 |
| 856 | 4 | _ | |y Restricted |u https://juser.fz-juelich.de/record/907585/files/1-s2.0-S0223523422002859-main.pdf |
| 856 | 4 | _ | |y Published on 2022-04-14. Available in OpenAccess from 2024-04-14. |u https://juser.fz-juelich.de/record/907585/files/EJMECH-D-21-03231_R2.pdf |
| 909 | C | O | |o oai:juser.fz-juelich.de:907585 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 0 |6 P:(DE-Juel1)180982 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 1 |6 P:(DE-Juel1)191040 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 2 |6 P:(DE-Juel1)131817 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 7 |6 P:(DE-Juel1)175142 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 8 |6 P:(DE-Juel1)180330 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 9 |6 P:(DE-Juel1)166419 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Natural, Artificial and Cognitive Information Processing |1 G:(DE-HGF)POF4-520 |0 G:(DE-HGF)POF4-525 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-500 |4 G:(DE-HGF)POF |v Decoding Brain Organization and Dysfunction |9 G:(DE-HGF)POF4-5253 |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |
| 915 | _ | _ | |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0 |0 LIC:(DE-HGF)CCBYNCND4 |2 HGFVOC |
| 915 | _ | _ | |a Embargoed OpenAccess |0 StatID:(DE-HGF)0530 |2 StatID |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b EUR J MED CHEM : 2015 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
| 920 | _ | _ | |l yes |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-5-20090406 |k INM-5 |l Nuklearchemie |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-Juel1)INM-5-20090406 |
| 980 | 1 | _ | |a FullTexts |
| 999 | C | 5 | |a 10.3390/ijms22084159 |9 -- missing cx lookup -- |1 Duclos |p 4159 - |2 Crossref |t Int. J. Mol. Sci. |v 22 |y 2021 |
| 999 | C | 5 | |a 10.1007/BF03178584 |9 -- missing cx lookup -- |1 Brady |p 90 - |2 Crossref |t Australas. Phys. Eng. Sci. Med. |v 31 |y 2008 |
| 999 | C | 5 | |a 10.1016/j.ejmech.2019.111979 |1 Goud |9 -- missing cx lookup -- |2 Crossref |t Eur. J. Med. Chem. |v 187 |y 2020 |
| 999 | C | 5 | |a 10.3389/fchem.2021.687678 |1 Scroggie |9 -- missing cx lookup -- |2 Crossref |t Front. Chem. |v 9 |y 2021 |
| 999 | C | 5 | |a 10.1021/jacs.0c09306 |9 -- missing cx lookup -- |1 Zheng |p 3753 - |2 Crossref |t J. Am. Chem. Soc. |v 143 |y 2021 |
| 999 | C | 5 | |a 10.1021/acs.jmedchem.7b01245 |9 -- missing cx lookup -- |1 Zlatopolskiy |p 189 - |2 Crossref |t J. Med. Chem. |v 61 |y 2018 |
| 999 | C | 5 | |a 10.2967/jnumed.118.218495 |9 -- missing cx lookup -- |1 Zlatopolskiy |p 817 - |2 Crossref |t J. Nucl. Med. |v 60 |y 2019 |
| 999 | C | 5 | |a 10.1039/D0CC02223C |9 -- missing cx lookup -- |1 Craig |p 9505 - |2 Crossref |t Chem. Commun. |v 56 |y 2020 |
| 999 | C | 5 | |a 10.3390/molecules25122880 |9 -- missing cx lookup -- |1 Zlatopolskiy |p 2880 - |2 Crossref |t Molecules |v 25 |y 2020 |
| 999 | C | 5 | |a 10.1021/acschemneuro.1c00284 |9 -- missing cx lookup -- |1 Hoffmann |p 3335 - |2 Crossref |t ACS Chem. Neurosci. |v 12 |y 2021 |
| 999 | C | 5 | |a 10.1016/j.jpba.2015.04.009 |9 -- missing cx lookup -- |1 Ory |p 209 - |2 Crossref |t J. Pharm. Biomed. Anal. |v 111 |y 2015 |
| 999 | C | 5 | |a 10.1039/C4OB01336K |9 -- missing cx lookup -- |1 Richarz |p 8094 - |2 Crossref |t Org. Biomol. Chem. |v 12 |y 2014 |
| 999 | C | 5 | |a 10.3390/molecules22122231 |9 -- missing cx lookup -- |1 Zarrad |p 2231 - |2 Crossref |t Molecules |v 22 |y 2017 |
| 999 | C | 5 | |a 10.1016/j.nucmedbio.2017.09.004 |9 -- missing cx lookup -- |1 Coenen |p v - |2 Crossref |t Nucl. Med. Biol. |v 55 |y 2017 |
| 999 | C | 5 | |a 10.7150/thno.23709 |9 -- missing cx lookup -- |1 Lewis |p 3991 - |2 Crossref |t Theranostics |v 8 |y 2018 |
| 999 | C | 5 | |a 10.3390/cancers13236030 |9 -- missing cx lookup -- |1 Krämer |p 6030 - |2 Crossref |t Cancers (Basel) |v 13 |y 2021 |
| 999 | C | 5 | |a 10.1016/j.ymeth.2017.05.019 |9 -- missing cx lookup -- |1 Langen |p 124 - |2 Crossref |t Methods |v 130 |y 2017 |
| 999 | C | 5 | |a 10.3389/fonc.2021.648187 |1 Xin |9 -- missing cx lookup -- |2 Crossref |t Front. Oncol. |v 11 |y 2021 |
| 999 | C | 5 | |a 10.1038/s41388-018-0275-3 |9 -- missing cx lookup -- |1 Puré |p 4343 - |2 Crossref |t Oncogene |v 37 |y 2018 |
| 999 | C | 5 | |a 10.2967/jnumed.120.244806 |9 -- missing cx lookup -- |1 Altmann |p 160 - |2 Crossref |t J. Nucl. Med. |v 62 |y 2021 |
| 999 | C | 5 | |a 10.3390/ph14101023 |9 -- missing cx lookup -- |1 Imlimthan |p 1023 - |2 Crossref |t Pharmaceuticals |v 14 |y 2021 |
| 999 | C | 5 | |a 10.1021/jm500031w |9 -- missing cx lookup -- |1 Jansen |p 3053 - |2 Crossref |t J. Med. Chem. |v 57 |y 2014 |
| 999 | C | 5 | |a 10.1007/s00259-021-05276-5 |9 -- missing cx lookup -- |1 Zinnhardt |p 174 - |2 Crossref |t Eur. J. Nucl. Med. Mol. Imag. |v 49 |y 2021 |
| 999 | C | 5 | |a 10.1007/978-1-0716-1712-0_17 |9 -- missing cx lookup -- |1 Werry |p 407 - |2 Crossref |v 173 |y 2022 |
| 999 | C | 5 | |a 10.1007/s00259-021-05308-0 |9 -- missing cx lookup -- |1 De Picker |p 164 - |2 Crossref |t Eur. J. Nucl. Med. Mol. Imag. |v 49 |y 2021 |
| 999 | C | 5 | |a 10.1016/j.jneumeth.2014.11.003 |9 -- missing cx lookup -- |1 Endepols |p 279 - |2 Crossref |t J. Neurosci. Methods |v 253 |y 2015 |
| 999 | C | 5 | |a 10.1021/acs.orglett.7b03950 |9 -- missing cx lookup -- |1 Zhou |p 812 - |2 Crossref |t Org. Lett. |v 20 |y 2018 |
| 999 | C | 5 | |a 10.1016/j.bmc.2005.06.030 |9 -- missing cx lookup -- |1 James |p 6188 - |2 Crossref |t Bioorg. Med. Chem. |v 13 |y 2005 |
| 999 | C | 5 | |a 10.1021/jacs.6b12911 |9 -- missing cx lookup -- |1 Schimler |p 1452 - |2 Crossref |t J. Am. Chem. Soc. |v 139 |y 2017 |
| 999 | C | 5 | |a 10.1039/D0CC04471G |9 -- missing cx lookup -- |1 Zhou |p 12546 - |2 Crossref |t Chem. Commun. (Camb). |v 56 |y 2020 |
| 999 | C | 5 | |a 10.1002/anie.202112375 |1 Smedley |9 -- missing cx lookup -- |2 Crossref |t Angew. Chem. Int. Ed. Engl. |v 61 |y 2022 |
| 999 | C | 5 | |a 10.1021/acs.orglett.7b02522 |9 -- missing cx lookup -- |1 Veryser |p 5244 - |2 Crossref |t Org. Lett. |v 19 |y 2017 |
| 999 | C | 5 | |a 10.1002/anie.201712429 |9 -- missing cx lookup -- |1 Guo |p 2605 - |2 Crossref |t Angew. Chemie Int. Ed. |v 57 |y 2018 |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|